We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
2012 - Review: Dipeptidyl peptidase-4 inhibitors do not increase overall adverse events in type 2 diabetes.
- Authors
Chatterjee, Saurav; Chatterjee, Sanjay
- Abstract
The article presents a double-blind, randomized controlled clinical trial study which was conducted to analyze whether dipeptidyl peptidase-4 (DPP-4) inhibitors increases risk in patients with type 2 diabetes. It mentions that results for adverse events, serious adverse events and mortality have showed no overall increase in health risk as compared with oral antidiabetic drugs. The study revealed that DPP-4 did not increase health risk as compared with antidiabetic drugs.
- Subjects
CONFIDENCE intervals; ENZYME inhibitors; HYPOGLYCEMIC agents; INFORMATION storage &; retrieval systems; MEDICAL databases; MEDLINE; META-analysis; TYPE 2 diabetes; SYSTEMATIC reviews; RANDOMIZED controlled trials; RELATIVE medical risk; BLIND experiment; TREATMENT duration; DESCRIPTIVE statistics
- Publication
ACP Journal Club, 2013, Vol 158, Issue 8, p1
- ISSN
1056-8751
- Publication type
Article
- DOI
10.7326/0003-4819-158-8-201304160-02008